All In Biotech

Drug Trial Radar · NCT07375758

A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.

A Phase I/II, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

130

Planned (sponsor's estimate)

Start

Feb 5, 2026

Primary completion

Jun 2028

Study completion Jun 2029

Sponsor

Sponsor type
Industry
First posted
Jan 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase I/II study designed to evaluate the safety, tolerability, PK and PD of subcutaneous MIL116, an anti-APRIL monoclonal antibody, in healthy participants and patients with IgA Nephropathy.

Conditions

  • Immunoglobulin A Nephropathy

Interventions

  • MIL116Drug

    MIL116 is supplied as sterile solution for subcutaneous (SC) injection.

  • Matching PlaceboDrug

    Placebo is to be administered at a matching volume by SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ia: Safety and Tolerability of Single Ascending Doses of MIL116 in Healthy Participants.Time frame: up to 6 months after enrollment
  2. Phase Ib: Safety and Tolerability of Multiple-Ascending Doses of MIL116 in IgAN Participants.Time frame: up to 18 months after enrollment
  3. Phase II: Change in Gd-IgA1 from Baseline at Week 12Time frame: up to 18 months after enrollment
  4. Change in 24-Hour Urine UPCR from Baseline at Week 24Time frame: up to 18 months after enrollment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.